Recombinant Fully Human Anti–PD-1 Monoclonal Antibody for Advanced Solid Tumors or Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
European Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Dose Escalation and Expansion (Phase Ia/Ib) Study of GLS-010, a Recombinant Fully Human Antiprogrammed Death-1 Monoclonal Antibody for Advanced Solid Tumors or Lymphoma
Eur. J. Cancer 2021 May 01;148(xx)1-13, D Liu, C Ma, P Lu, J Gong, D Ye, S Wang, P Peng, Y Bai, Y Song, J Chen, O Jiang, G Zhang, Y Ba, L Chen, J Pan, Q Li, L Zhang, S Gu, X Yin, B Cao, W Han, H Dong, J Guo, H Zhang, H Su, Y Jiang, W Ouyang, L Ma, Y Sun, F Zhang, J Lv, Y Guo, C Xu, J Qi, L Wang, X Wang, Z Liu, L ShenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.